78299-75-9 Usage
Uses
Used in Pharmaceutical and Agrochemical Industries:
5-BENZYLOXY-1H-INDAZOLE is used as a building block for the synthesis of various pharmaceuticals and agrochemicals, leveraging its antimicrobial and antifungal properties to develop new drugs and pesticides.
Used in Antimicrobial Applications:
5-BENZYLOXY-1H-INDAZOLE is used as an antimicrobial agent for its ability to inhibit the growth of bacteria and fungi, making it a potential candidate for treating infections and developing new antimicrobial drugs.
Used in Antifungal Applications:
5-BENZYLOXY-1H-INDAZOLE is used as an antifungal agent to combat fungal infections, offering a potential therapeutic option for treating conditions caused by fungal pathogens.
Used in Cancer Treatment Research:
5-BENZYLOXY-1H-INDAZOLE is used as a research compound in the study of cancer treatment, exploring its potential to target and inhibit the growth of cancer cells, offering a new avenue for developing anticancer drugs.
Used in Inflammation Treatment Research:
5-BENZYLOXY-1H-INDAZOLE is used in research aimed at treating inflammation, examining its potential to modulate inflammatory responses and develop new anti-inflammatory medications.
Used in Organic Synthesis and Medicinal Chemistry Research:
5-BENZYLOXY-1H-INDAZOLE is used as a reagent in organic synthesis and medicinal chemistry due to its versatile reactivity, facilitating the development of new chemical compounds and therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 78299-75-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,8,2,9 and 9 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 78299-75:
(7*7)+(6*8)+(5*2)+(4*9)+(3*9)+(2*7)+(1*5)=189
189 % 10 = 9
So 78299-75-9 is a valid CAS Registry Number.
InChI:InChI=1/C14H12N2O/c1-2-4-11(5-3-1)10-17-13-6-7-14-12(8-13)9-15-16-14/h1-9H,10H2,(H,15,16)
78299-75-9Relevant academic research and scientific papers
Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides
Laufer, Radoslaw,Ng, Grace,Liu, Yong,Patel, Narendra Kumar B.,Edwards, Louise G.,Lang, Yunhui,Li, Sze-Wan,Feher, Miklos,Awrey, Don E.,Leung, Genie,Beletskaya, Irina,Plotnikova, Olga,Mason, Jacqueline M.,Hodgson, Richard,Wei, Xin,Mao, Guodong,Luo, Xunyi,Huang, Ping,Green, Erin,Kiarash, Reza,Lin, Dan Chi-Chia,Harris-Brandts, Marees,Ban, Fuqiang,Nadeem, Vincent,Mak, Tak W.,Pan, Guohua J.,Qiu, Wei,Chirgadze, Nickolay Y.,Pauls, Henry W.
, p. 4968 - 4997 (2014/10/16)
TTK kinase was identified by in-house siRNA screen and pursued as a tractable, novel target for cancer treatment. A screening campaign and systematic optimization, supported by computer modeling led to an indazole core with key sulfamoylphenyl and acetamido moieties at positions 3 and 5, respectively, establishing a novel chemical class culminating in identification of 72 (CFI-400936). This potent inhibitor of TTK (IC50 = 3.6 nM) demonstrated good activity in cell based assay and selectivity against a panel of human kinases. A co-complex TTK X-ray crystal structure and results of a xenograft study with TTK inhibitors from this class are described.
KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
-
Page/Page column 152-153, (2011/10/31)
The present teachings provide a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are a pharmaceutical composition and method of use thereof.
